The hormonal family of vasoinhibins, which derive from the anterior pituitary hormone prolactin, are 3 known for their inhibiting effects on blood vessel growth, vasopermeability, and vasodilation. As pleiotropic 4 hormones, vasoinhibins act in multiple target organs and tissues. The generation, secretion, and regulation of 5 vasoinhibins are embedded into the organizational principle of an axis, which integrates the hypothalamus, the 6 pituitary, and the target tissue microenvironment. This axis is designated as the prolactin/vasoinhibin axis. 7
precursor PRL molecule. It is this structural and functional distinctiveness that confers the identity to the 23
vasoinhibin-family. 24
Vasoinhibins, as defined by their characterization as a family, are not a single species, instead their 25 molecular mass ranges between 11 and 18 kDa. This is due to the generation of vasoinhibins through proteolytic 26 cleavage of PRL by several endogenous proteolytic enzymes, namely cathepsin D (8, 79), matrix 27 metalloproteinases (69), and bone morphogenetic protein -1 (BMP-1) (45). Since these enzymes cleave full-28 length PRL at various sites near or within the long loop connecting the third and the fourth α-helix, proteolysis 29 by these enzymes results in the synthesis of vasoinhibins of varying molecular masses. Vasoinhibins all share the 30 N-terminal region of full-length PRL. The C-terminal fragment that arises from the proteolysis of PRL does not 31 possess vasoinhibin-like activities (62) . 32
The roots of discovery of vasoinhibins date back to the year 1980, when PRL-fragments were first 33 detected in extracts of the rodent pituitary cells (73) . Soon thereafter, PRL-fragments were found in the human 34 pituitary gland and plasma (87). It was observed that PRL-fragments are not only present in the pituitary gland, 35 but are also synthesized in vitro by the rat prostate gland (27, 28) , mammary gland, kidney and liver (15, 108) .
48
Vasoinhibin-generation in the pituitary gland occurs by proteolytic cleavage of their immediate precur-49 sor PRL by cathepsin D. Studies in rodents revealed that vasoinhibins are generated in the adenohypophysis, 50
where, in the secretory granules of PRL, cathepsin D cleaves full-length PRL to yield vasoinhibins (34) . 51
Pituitary vasoinhibin-generation is thus closely intertwined with PRL-production. This is imperative, as 52 vasoinhibins are not a product of a separate mRNA (73, 85) , but are generated by a posttranslational 53 modification, proteolytic cleavage, of PRL. However, the ratio of vasoinhibin generation to PRL synthesis is not 54 fixed, instead it varies under physiological control. For example, the female, virgin rat features a pituitary 55 vasoinhibin/PRL ratio of 0.22. During pregnancy however, this ratio increases to 0.37 on day 9 and further to 56 0.77 on day 12 (73). Consistent with these observations, plasma levels of vasoinhibins during the third trimester 57 of human pregnancy are higher compared to non-pregnant states (87). The ratio of vasoinhibin-to-PRL synthesis 58 is accessible to pharmacologic manipulation, as demonstrated by the increase of the vasoinhibin/PRL ratio from 59 0.22 in the non-treated rat, to 0.99 after treatment with perphenazine, a dopamine D1 and D2 receptor antagonist 60 that stimulates the production and release of PRL by the pituitary gland (73). The ratio is also increased by 61 treatment with estrogen and reduced by thyrotropin releasing hormone (34, 40, 73) . Thus, vasoinhibins possess 62 the characteristics of effector hormones secreted from the anterior pituitary gland, similar to PRL, except that 63 they feature posttranslational modification from the latter. These series of events, expression and 64 posttranslational modification of PRL, and subsequent secretion by exocytosis, resembles the generation of other 65 hormones synthesized from a prohormone. Parallel examples are the generation of the adrenocorticotropic 66 hormone (ACTH) and it's related peptide-hormones generated in the corticotroph cells of the adenohypophysis 67 by proteolytic cleavage of their precursor proopiomelanocortin (POMC) (105); and the thyroid hormone axis 68 (TRH, TSH, T4/T3) where the bioactive T3 is processed from T4 by local deiodinases at the target tissue level. 69
It is also evident that vasoinhibin levels at the target tissue are regulated by the abundance of circulating 70 PRL secreted by the pituitary gland. This is demonstrated by the observation that the induction of 71 hyperprolactinaemia in rodents leads to vasoinhibin accumulation within the retina. Vice versa, pharmacological 72 inhibition of pituitary PRL-secretion with the dopamine agonist bromocriptine lowers the level of retinal 73 vasoinhibins (5). Another situation in which vasoinhibin-level at the target tissue depend on systemic PRL 74 concentration is demonstrated in rodent studies investigating the role of vasoinhibins in peripartum 75 cardiomyopathy (PPCM). Female mice receiving a chronic infusion of recombinant PRL had higher left 76 ventricular myocardial vasoinhibin levels than controls (54) . 77
The third tier at which vasoinhibin-levels are regulated, next to intrapituitary regulation of the 78 vasoinhibin/PRL ratio and total pituitary PRL secretion, is the expression and activity of the PRL-converting 79 enzymes at the target tissue level. This is observed in mice with experimentally induced PPCM, where higher 80 left ventricular vasoinhibin levels associate with increased protein concentration and activity of cathepsin D (54) . 81 This is also observed in the placenta of women with diabetes mellitus type 1, in which, compared to controls, 82 increased vasoinhibin generation associates with a higher expression of the PRL-cleaving enzyme BMP-1. Of 83 note, placental mRNA PRL-expression is also higher, suggesting that upregulation of local PRL-synthesis can 84 serve the purpose of providing sufficient amounts of substrate required for local vasoinhibin generation (78). 85
Three principles can be derived from the above observations. First, vasoinhibins are generated in the 86 anterior pituitary gland from which they are secreted as effector hormones. Second, the central, anterior pituitary 87 generation of vasoinhibins is under physiologic control over the total anterior pituitary PRL production and 88 activity of the PRL converting proteases. Third, the regulation of vasoinhibin concentration at the target tissue 89 level includes the utilization of circulating and locally-produced PRL and the level of activity of local PRL 90 cleaving enzymes. Thus, it appears that generation, secretion, and regulation of vasoinhibin action demonstrate 91 the organizational principle of an axis that integrates the hypothalamus, the pituitary, and the target tissue level 92 (Figure 1 ). Indeed, this corresponds with the classical three tiers of control which subserve the regulation of 93 anterior pituitary hormone secretion (82) . Furthermore, the generation of vasoinhibins at the target tissue level 94 represents a novel example of paracrinology, an exciting concept in endocrinology by which hormone action is 95 being regulated at the target tissue microenvironment (56). 96
97

III. MOLECULAR SPECIES, DISTRIBUTION, AND TARGET TISSUES 98
Cleavage of human PRL by cathepsin D results in the generation of vasoinhibins comprising residues 1-99 80-85 (11kDa), 1-150 (17.2 kDa), 1-147 (16.8 kDa), and 1-132 (15 kDa) (79). Cleavage of PRL by MMP results 100 in vasoinhibins comprising residues 1-150 (17.7 kDa), 1-132 (16.8 kDa), 1-124 (14.1 kDa), and 1-111 (12.5 101 kDa) (69). MMP cleave PRL to generate vasoinhibins with the following relative potency: MMP-8 > MMP-13 > 102 MMP-3 > MMP-1 > MMP-2 > MMP-9 (69). Proteolysis of PRL by BMP-1 synthesizes a single vasoinhibin 103 species comprising residue 1-152 (17 kDa) (45). Oxidative stress can increase the activity of cathepsin D to 104 cleave PRL (54), whereas hypoxia decreases cathepsin D-induced vasoinhibin generation (33). A higher 105 expression of cathepsin D and a parallel increase in vasoinhibin generation is also observed during mammary 106 gland involution (58). The activity of MMP from chondrocytes to generate vasoinhibins seems to be higher in 107 patients with arthritis (69), pointing towards the possibility of an induction of vasoinhibin generation by 108 inflammatory factors. Factors associated with the activity of BMP-1 in the generation of vasoinhibins are not 109
known. 110
Vasoinhibin species are detected in the rat (34, 73), mouse (86), and human (79, 87) pituitary gland, the 111 human vascular endothelium (30), the human and rat placenta (78), the bovine corpus luteum (38), and the 112 following rodent tissues: hypothalamus (110), neurohypophysis (25), cartilage (69), and retina (4, 5). However, 113 the placental localization of vasoinhibins may be questioned since placental samples can be contaminated with 114 decidua and both human and rodent decidua produce PRL (52, 76) . Of note, in vitro studies demonstrate that 115 these and the following tissues synthesize vasoinhibins when exposed to full-length PRL: heart (54), ventral 116 prostate, spleen, lung, kidney and mammary gland (8, 15, 27, 28, 58, 108) in rodents and the mammary gland (7) 117 and placenta (47) in humans. Vasoinhibin species are also detected in human and rat plasma/serum (37, 47, 87, 118 98), in human amniotic fluid (43, 47), subretinal fluid (37), and urine (47, 65) . A summary of the distribution 119 and functions of vasoinhibins in the human and the rodent organism is presented in Table 1 . 120
The presence of vasoinhibins in the pituitary gland and plasma reflects their hormonal nature, that is 121 their generation and secretion by an endocrine gland into the circulation. However, vasoinhibins can also act 122 locally at their production site, as demonstrated in rodent studies in which antiproliferative and proapoptotic 123 actions of vasoinhibins were observed in the anterior pituitary gland (40). In case of the hypothalamic 124 paraventricular nuclei and the supraoptic nucleus, it appears that vasoinhibins function as stimulators of 125 vasopressin release (71) and as antagonists of vascular endothelial growth factor (VEGF), whose expression is 126 particularly high at these sites (25, 60 ). An antagonism to the effects of VEGF may also operate in cartilage, an 127 avascular tissue (69) and is observed in the rat retina, in which vasoinhibins reduce VEGF-and diabetes-induced 128 retinal vasopermeability (5, 44). Indeed, because of the close anatomical vicinity of vascularized tissues and 129 avascular compartments, the eye, in which vasoinhibins control ocular angiogenesis, vasodilation, and vascular 130 permeability, is one of the best-characterized target organs for vasoinhibins, and represents a key illustrative 131 example of the actions of vasoinhibins (4, 21, 22, 44, 77, 99 Whether the effects of vasoinhibins in the above mentioned target tissues is due to their action on the 136 vessel system in these tissues or on a tissue-specific cell-type is not always clear. The vasoinhibin effect in the 137 heart however, in which vasoinhibins utilize the cardiomyocyte to exert their effect on the heart's vasculature, 138 points to the possibility of a complex interplay between both, vascular and non-vascular cells. Further, the 139 proportion as to which the total amount of vasoinhibins present in a target tissue is of systemic or local origin is 140 PAI-1 is a serine protease inhibitor that by inhibiting tissue-type plasminogen activator (t-PA) and urokinase-162 type plasminogen activator (u-PA) blocks the generation of plasmin from plasminogen and suppresses clot 163 dissolution (36). PAI-1 forms a complex with uPA and uPAR on endothelial cell membranes (12). Of note, 164 vasoinhibins upregulate PAI-1 expression in endothelial cells (66) and were recently reported to form a complex 165 with endogenous PAI-1 in the culture medium of these cells, as well as in human and mouse plasma (6). 166
Vasoinhibins also colocalized with the PAI-1-uPA-uPAR complex on the endothelial cell surface and formation 167 of such multiprotein complex was required for the antiangiogenic activity of vasoinhibins. This was concluded 168 from experiments demonstrating that silencing or pharmacological blockage of PAI-1 and uPAR signaling 169 abrogated the antiangiogenic effect of the vasoinhibins in HUVEC (6). Of note, the apparent molecular weight of 170 the binding proteins (52 kDa and 32 kDa) of the above mentioned high affinity vasoinhibin binding site (26), is 171 close to the molecular masses of PAI-1 (43 kDa), uPA (51 kDa), and uPA receptor (55 kDa) and their identity 172 could indeed be the PAI-1-uPA-uPAR complex. However, the specific binding affinity of vasoinhibins to these 173 endothelial membrane species was much higher (Kd = 10 nM) than to PAI-1 (1 μM) or uPA-PAI-1 (0.5 μM). 174
While the difference in affinity may suggest a higher Kd for the natural multicomponent PAI-1-uPA-uPA 175 receptor complex, the contribution of other vasoinhibin binding sites, for example a new cell surface receptor, 176 cannot be disregarded and continues to be an unresolved question. 177
A role further downstream in the vasoinhibin-signaling cascade, downstream from a potential cell 178 surface receptor or signaling via PAI-1-uPA-uPAR, is described for the vasoinhibin-miR146a (microRNA-146a) 179
circuit. It appears from the studies in PPCM-models, that vasoinhibins mediate part of their antiangiogenic 180 effects via induction of miR146a in endothelial cells. If exposed to vasoinhibins, HUVEC proliferation is 181 reduced via upregulation of miR146a, and HUVEC release miR146a-loaded exosomes that can be absorbed by 182 neonatal rat cardiomyocytes (51). In these cardiomyocytes, miR146a has a detrimental effect and reduces 183 cardiomyocyte metabolic activity-an effect that presumably contributes to the pathogenesis of PPCM (51 Vasoinhibins are synthesized in the human placenta with higher rates observed in placentas from women 210 with preeclampsia (70) and type 1 diabetes mellitus (78). Furthermore, vasoinhibins are elevated in serum, urine, 211 and amniotic fluid of women with preeclampsia as compared to normotensive controls, and their occurrence in 212 urine increases with the severity of the disease and the occurrence of adverse outcomes (47, 64, 65) . In fact, the 213 presence of vasoinhibins in urine predicts adverse maternal and perinatal outcomes. The odds ratio in women 214 with preeclampsia and urinary vasoinhibins for combined adverse maternal outcomes (pulmonary edema, acute 215 renal failure, placental abruption, hepatic hematoma or rupture, intubation required and use of inotropics) is 44.9 216 (95 % CI 5.1 -392.3), for stillbirths or neonatal deaths is 1.3 (95% CI 0.4 -3.6), and for small for gestational 217 age infants is 1.9 (95% CI 1.1 -3.1) (64). The antiangiogenic effects of vasoinhibins and the paramount 218 importance of an adequate vascularization of the placenta imply a causal link between vasoinhibins and these 219 outcomes. Furthermore, human and rat placental tissue featuring higher vasoinhibin synthesis in the presence of 220 maternal diabetes demonstrates hypovascularization with reduced vascular surfaces and capillary density (78). 221
Also, the level of vasoinhibins in amniotic fluid from patients with preeclampsia is inversely correlated with 222 birth weight, that is higher vasoinhibin level in the amniotic fluid associates with lower birth weight (47), and 223 vasoinhibins antagonize the proangiogenic actions of VEGF in amniotic fluid from patients with preeclampsia 224 (47). These outcomes as well as the pregnancy associated diseases of preeclampsia and PPCM share a common 225 milieu of increased inflammation, a factor in the activation of the proteolytic enzyme cathepsin D. Therefore, it 226 is conceivable that a higher placental synthesis of vasoinhibins, combined with their increased pituitary release 227 into the circulation during pregnancy, contributes to abnormal placental vascularization and thus to intrauterine 228 growth restriction and small for gestational age infants. Indeed, the regulation of factors stimulating and 229 inhibiting growth between the maternal organism and the fetoplacental unit is usually resolved at the level of the 230 maternal reproductive tract. However, in the fetoplacental unit, a pathophysiologic increased synthesis of 231 vasoinhibins may disrupt the balance of growth factors and their inhibitors that contributes to adverse maternal 232 and perinatal outcomes. This disruption is also speculated to occur at the level of organ dysfunction seen in 233 association with increased vasoinhibins, such as the cardiac myocyte (PPCM (54, 55)), the endothelium 234 (preeclampsia (47, 64)), the kidney (preeclampsia (47, 64)), and as above, the placenta (preeclampsia, fetal 235 growth abnormalities). Clinical studies in women with PPCM using bromocriptine to suppress PRL secretion 236 and cardiac vasoinhibin synthesis point towards beneficial effects, and a randomized, multicenter clinical trial is 237 currently under way (49, 50, 53, 88) . 238 239
VI. UNRESOLVED QUESTIONS 240
Prolactin and growth hormone (GH) are phylogenetically related, they evolved from a common ancestral 241 gene (75) and share a long-chain class-I helical cytokine structure comprising four α-helices. Placental lactogen 242 (PL), the third member of the GH/PRL/PL-family, and another class-I helical cytokine, arose independently by 243 duplication of the PRL gene in rodents and ruminants and by duplication of the GH gene in primates (42). GH 244 and PL likely contribute to the generation of endogenous vasoinhibins, however the generation and effects of 245 GH-and PL-derived vasoinhibins have received little attention. Recombinant vasoinhibins derived from GH and 246 PL displayed antiangiogenic effects in vitro (92). However, no information about their endogenous generation 247 and clinical relevance is available. Importantly, GH-derived, vasoinhibin-like fragments were not detected in the 248 rat pituitary, suggesting that any possible, endogenously GH-derived vasoinhibins may not be synthesized in the 249 pituitary gland (73). Thus, the contribution of GH and PL-cleavage resulting in the synthesis of vasoinhibins to 250 the function or regulation of the prolactin/vasoinhibin axis is unclear. The observation that GH is not converted 251 to vasoinhibins in the rat pituitary, suggests that the possible contribution of GH to the total endogenous 252 vasoinhibin level is restricted to the peripheral tissue level. Placental lactogen is increased in pregnancy, and is 253 produced by the human placenta. It is not known whether PL is converted to vasoinhibins at the level of the 254 placenta as well. 255
It is unclear if the differences in molecular mass impact the structure and function of vasoinhibins. Also, 256 it remains to be shown whether and to what extent each of the various proteases contributes to the physiological, 257 endogenous level of vasoinhibins, and how the synthesis of different vasoinhibins is modified in disease 258 conditions. Accordingly, the total composition and full identity of endogenous vasoinhibins in the circulation 259 and at the target-tissue levels, including their interplay, has yet to be determined. The impact of glycosylation of 260 PRL on vasoinhibin-physiology is unknown. It is possible, however, that glycosylation alters the proteolytic 261 cleavage of PRL and may thus impact vasoinhibin generation, as well as the action and clearance of these 262 peptides (10). These unresolved questions have delayed the development of a uniform 263 classification/nomenclature for vasoinhibins (97). 264
Another major unresolved question is the normal concentration of endogenous vasoinhibins in the 265 human circulation. This is owing to the lack of a quantitative assay, with which circulating vasoinhibin levels 266 and reference ranges could swiftly be established. The only method for the evaluation of endogenous 267 vasoinhibins, which is considered relatively reliable is immunoprecipitation and Western Blotting. However, this 268 method is only semi-quantitative and subject to significant interassay variability. Mass spectrometric techniques 269 were successfully adapted to determine vasoinhibins in sera (106), however these techniques are experimental 270
and not commercially available. The urgent need for a quantitative assay for vasoinhibins is further underscored 271
by the clinical implications of vasoinhibins in diabetic complications, cancer, and pregnancy-associated diseases, 272 in which the quantitation of circulating vasoinhibins are of relevance for diagnosis, treatment, and risk 273 stratification. 274
VII. PHYLOGENETIC CONTEXT 275
Prolactin is a pleiotropic hormone whose functions are classified into seven categories: water and 276 electrolyte balance, growth and development, endocrinology and metabolism, brain and behaviour, reproduction, 277 immunoregulation and protection, and actions associated with pathological disease states ( representative species of several major taxons is presented in Table 5 . Indeed, while 5 cleavage sites are present 307 in the human and the gorilla PRL, four cleavage sites are present in the the macacue, three in the pig and the 308 oppossum, two in the duck and in the xenopus tropicalis, and none in the zebrafish and the spotted gar (Table 5) . 309
It appears thus, that vasoinhibins emerged in tetrapods and that throughout speciation, there was an increase in 310 cleavage sites with the highest number of cleavage sites present in primate species. Along this line, the ability of 311 vasoinhibins to balance blood vessel growth, function, and involution could have contributed to PRL effects 312 throughout vertebrate phylogeny and to its value as a biologically conserved factor (1, 20) . A limiting factor is 313 that the selected species may represent exceptions rather than representatives of the rule. A full comparative 314 genomics approach will help to strengthen this analysis. 315
An additional level of complexity, beyond the scope of this review, is the contribution of other members 316 of the PRL family in rodents, such as proliferins and proliferin-related proteins known to have effects on blood 317 vessels (31, 89). This also applies for species-specific GH or PRL family gene expansions in different species 318 including primates, rodents and ruminants (2, 102, 103, 107) . 319 320
VIII. PERSPECTIVES AND SIGNIFICANCE 321
The process of vasoinhibin generation and secretion from the anterior pituitary gland appears to be under 322 physiological control through mechanisms affecting the biosynthesis of PRL and the expression/activity of PRL 323 cleaving proteases. Also, the circulating PRL-levels and the local synthesis of PRL affect the peripheral 324 generation of vasoinhibins at the target tissue level. Therefore, the generation, secretion, and regulation of 325 vasoinhibin action are embedded into the organizational principle of an axis, which integrates the hypothalamus, 326 the pituitary, and the target tissue microenvironment. On the basis of the established nomenclature for other 327 endocrine axes, this axis is designated as the prolactin/vasoinhibin axis. The significance of the 328 prolactin/vasoinhibin axis in pathophysiological states is surfacing to provide a better understanding of the role 329 of PRL in clinically apparent disease conditions. Among these, diseases associated with the state of pregnancy 330 are most prominent, as profound changes in PRL metabolism during pregnancy and postpartum seem to render 331 the prolactin/vasoinhibin axis particularly susceptible for disturbances that would cause major changes in the 332 production/action of vasoinhibins. Recent studies concerned with the search for vasoinhibin signaling 333 mechanisms, and particularly with the cell surface receptor involved in their actions, are providing valuable 334 insights into the complexity of vasoinhibin actions within the vascular and non-vascular microenvironment. 335
This review brings into focus major research challenges needed to advance the field in the near and 336 mediate future. A systematic approach is required to help identify the physiologically relevant vasoinhibin 337 molecules and the cleaving proteases that generate them. This approach should include the characterization 338 through uniform conditions of their antiangiogenic, antivasopermeability, antivasodilatatory effects, and 339 signaling mechanisms. This knowledge will help develop a proper nomenclature for the definition of the various 340 endogenous vasoinhibin isoforms and the development of a quantitative assay capable of differentiating them 341 and their precursor proteins (PRL, GH, PL) in body fluids. The latter is a major demand for studying the 342 involvement of vasoinhibins in pregnancy-associated diseases, diabetic complications, and cancer and for their 343 implications in risk stratification, diagnosis, and treatment. Naturally, resolving the solution structure of 344 vasoinhibins by NMR-spectroscopy, possibly by analyzing recombinant human vasoinhibins, would enhance our 345 understanding of the structure-function relationships of the vasoinhibin-family and produce valuable insights 346 into their mechanism of action. Upon successful resolution of these issues, the knowledge of the role of 347 vasoinhibins in health and disease will be greatly enhanced and the development of a sustainable classification of 348 vasoinhibins that provides orientation in future biomedical research, will commence. 349
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